Photo of Lisa C. Silbert, M.D., M.C.R.

Lisa C. Silbert M.D., M.C.R.

Lisa C. Silbert, MD, MCR, FAAN, is an Associate Professor in the Department of Neurology at Oregon Health & Science University School of Medicine, Director of the Neuroimaging Core at the Oregon Aging and Alzheimer's Disease Center, Director of the Dementia Clinic at the VA Portland Health Care System, and a Clinical Research Concentration Lead for the OHSU SOM Scholarly Projects course. She completed her neurology residency at UCLA and fellowship training in both Geriatric Neurology and Clinical Neurophysiology at OHSU. Dr. Silbert's clinical practice consists primarily of patients with neurodegenerative disease affecting cognitive function, and intraoperative neurophysiological monitoring.

Dr. Silbert's research focuses on the effects of cerebral white matter ischemic change on cognitive and motor function in the elderly. Her studies include investigations of how differing rates of white matter damage affect cognition, how changes in cerebral blood flow and microstructural white matter integrity impact expansion of white matter hyperintensity lesions, and the utilization of post-mortem high field MRI for targeted histopathological characterization of small vessel cerebrovascular disease. She has received funding for this work from the Alzheimer's Association, the American Academy of Neurology Foundation, and the NIH/NIA, including a K23/Paul B. Beeson career development award in aging research and an R01.

Read more
  • Residency:

    • University of California, Los Angeles - Neurology Residency
  • Fellowship:

    • Oregon Health & Science University - Clinical Neurophysiology and Geriatric Neurology
  • Certifications:

    • ABPN


  • "Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging" Neurology January 24 2012
  • "Impact of white matter hyperintensity volume progression on rate of cognitive and motor decline" Neurology July 8 2008
  • "Trajectory of white matter hyperintensity burden preceding mild cognitive impairment" Neurology August 21 2012
  • "A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer's disease" Journal of Alzheimer's Disease  2014
  • "Nutrient biomarker patterns, cognitive function, and MRI measures of brain aging" Neurology April 17 2012
  • "Mild hypothermia, blood loss and complications in elective spinal surgery" Spine Journal March 2004
  • "Neuropathologic basis of age-associated brain atrophy" JAMA Neurology  2013
  • "Characterizing the white matter hyperintensity penumbra with cerebral blood flow measures" NeuroImage: Clinical June 8 2015
  • "Prevalence of dementia in Chamorros on Guam" Neurology May 2007
  • "Trajectories of brain loss in aging and the development of cognitive impairment" Neurology March 2008
  • "Role of soluble epoxide hydrolase in age-related vascular cognitive decline" Prostaglandins and Other Lipid Mediators September 30 2014
  • "Plasma omega-3 PUFA and white matter mediated executive decline in older adults" Frontiers in Aging Neuroscience  2013
  • "Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease" Annals of Neurology  2002
  • "Natural history of cognitive decline in the old old" Neurology May 13 2003
  • "Neuroimaging and cognition in parkinson's disease dementia" Brain Pathology May 2010
  • "Neuropathologic basis of white matter hyperintensity accumulation with advanced age" Neurology September 10 2013
  • "Does statin use decrease the amount of Alzheimer disease pathology in the brain?" Neurology August 2007
  • "At the interface of sensory and motor dysfunctions and Alzheimer's disease" Alzheimer's and Dementia  2015
  • "Cortical excitability and age-related volumetric MRI changes" Clinical Neurophysiology May 2006
  • "TMEM106B is a genetic modifier of frontotemporal lobar degeneration with C9orf72 hexanucleotide repeat expansions" Acta Neuropathologica March 2014
  • "Microcephaly genes and risk of late-onset Alzheimer disease" Alzheimer Disease and Associated Disorders July 2011
  • "Aberrant detergent-insoluble excitatory amino acid transporter 2 accumulates in alzheimer disease" American Journal of Psychotherapy July 2010
  • "Changes in premorbid brain volume predict Alzheimer's disease pathology" Neurology August 26 2003
  • "Cycad exposure and risk of dementia, MCI, and PDC in the Chamorro population of Guam" Neurology May 2007
  • "The "S" in MELAS" Journal of Stroke and Cerebrovascular Diseases November 1996
  • "Brain volumes in Guam dementia vs Parkinson dementia complex vs aging Chamorro adults" Neurology July 2007
  • "Cognitive impairment risk" Neurology July 2009
  • "Use of percutaneous endoscopy to place syringopleural or cystoperitoneal cerebrospinal fluid shunts" Journal of neurosurgery. Spine April 2005
  • "Biomarker progressions explain higher variability in stage-specific cognitive decline than baseline values in Alzheimer disease" Alzheimer's and Dementia November 1 2014
  • "Depressive symptoms are associated with late life cognitive decline independent of common age-related pathologies" Evidence-Based Mental Health  2015

Additional information

Edit profile